LXRX Financial Facts
Collaborative research: 27.69MSubscription and license fees: 31K
See Full Income Statement
Accumulated deficit: -1.22B
Total current liabilities: 170.11M
See Full Balance Sheet
Lexicon Pharmaceuticals, Inc. (LXRX) Earnings
|
Expand Research on LXRX
| Next EPS Date | 7/30/26 | EPS Growth Rate | -600.0% |
|---|---|---|---|
| Average EPS % Beat Rate | +74.2% | Revenue Growth Rate | -86.1% |
| Average % Move 1-Wk after EPS | +15.3% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
7/30/26  |
Q226 | N/A | -$0.05 | N/A | N/A | $4M | N/A | N/A | N/A | ||
| 5/7/26 | Q126 | $0.00 | -$0.04 | +$0.04 | $21.1M | $9.78M | N/A |  | | Details | |
| 5/4/26 |
Q126 | N/A | -$0.04 | N/A | N/A | $9.78M | N/A | N/A | N/A | ||
| 5/1/26 |
Q126 | N/A | -$0.04 | N/A | N/A | $9.78M | N/A | N/A | N/A | ||
| 4/30/26 |
Q126 | N/A | -$0.04 | N/A | N/A | $9.78M | N/A | N/A | N/A | ||
| 3/5/26 | Q425 | -$0.04 | -$0.07 | +$0.03 | $5.5M | $3.92M | N/A | | | Details | |
| 11/6/25 | Q325 | -$0.04 | -$0.07 | +$0.03 | $14.1M | $4.65M | N/A | | | Details | |
| 10/30/25 |
Q325 | N/A | -$0.07 | N/A | N/A | $4.65M | N/A | N/A | N/A |
